CervoMed (NASDAQ:CRVO) Upgraded by Wall Street Zen to “Sell” Rating

Wall Street Zen upgraded shares of CervoMed (NASDAQ:CRVO) from a strong sell rating to a sell rating in a research note issued to investors on Saturday.

A number of other equities research analysts also recently weighed in on the stock. D. Boral Capital reiterated a “buy” rating and issued a $31.00 price target on shares of CervoMed in a research report on Wednesday, April 22nd. Roth Capital set a $9.00 price target on CervoMed in a research note on Monday, May 18th. Chardan Capital raised CervoMed to a “strong-buy” rating in a research report on Monday, August 3rd. Weiss Ratings lowered CervoMed from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of CervoMed in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $21.50.

CervoMed Stock Performance

NASDAQ:CRVO opened at $2.73 on Friday. CervoMed has a 52 week low of $2.13 and a 52 week high of $11.25. The firm has a market cap of $41.28 million, a price-to-earnings ratio of -0.85 and a beta of -0.63. The firm’s 50-day simple moving average is $3.11 and its 200 day simple moving average is $3.74.

CervoMed (NASDAQ:CRVO) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.22. CervoMed had a negative net margin of 672.80% and a negative return on equity of 156.02%. Sell-side analysts anticipate that CervoMed will post -2.4 EPS for the current year.

Insider Transactions at CervoMed

In other news, Director Joshua S. Boger bought 955,414 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were purchased at an average cost of $3.14 per share, with a total value of $2,999,999.96. Following the acquisition, the director directly owned 1,795,865 shares in the company, valued at $5,639,016.10. This represents a 113.68% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 35.80% of the stock is owned by insiders.

Institutional Trading of CervoMed

Institutional investors and hedge funds have recently made changes to their positions in the company. Rhumbline Advisers boosted its position in shares of CervoMed by 35.5% during the 1st quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock worth $53,000 after acquiring an additional 1,526 shares in the last quarter. Marshall Wace LLP acquired a new position in CervoMed during the second quarter valued at approximately $76,000. XTX Topco Ltd acquired a new position in CervoMed during the fourth quarter valued at approximately $81,000. Jane Street Group LLC bought a new stake in CervoMed during the fourth quarter worth $88,000. Finally, Dimensional Fund Advisors LP bought a new stake in CervoMed during the fourth quarter worth $110,000. Institutional investors own 25.15% of the company’s stock.

Key Headlines Impacting CervoMed

Here are the key news stories impacting CervoMed this week:

• Positive Sentiment: HC Wainwright raised multiple earnings forecasts and reaffirmed its Buy rating. The firm reduced its projected loss for FY2026 to $2.32 per share from $2.70, FY2027 to $1.90 from $1.99, Q3 2026 to $0.48 from $0.60, and Q4 2026 to $0.48 from $0.59. It also improved its Q1 and Q2 2027 loss estimates to $0.46 and $0.41 per share, respectively. HC Wainwright Reaffirms Buy Rating for CervoMed
• Positive Sentiment: Brookline Capital Markets also sharply improved its loss forecasts. The firm lowered its FY2026 projected loss to $2.97 per share from $4.34, while reducing its Q3 and Q4 2026 loss estimates to $0.73 and $0.75 per share from $1.04 and $1.55, respectively. These revisions indicate expectations for better-than-previously-anticipated financial performance.
• Neutral Sentiment: The estimate changes still imply substantial ongoing losses. HC Wainwright’s forecasts remain negative for every listed quarter, and the consensus estimate for CervoMed’s current fiscal year is a $2.50-per-share loss. Investors may therefore view the revisions as incremental rather than evidence of near-term profitability.
• Negative Sentiment: Shares have decreased even with the improved outlook. CervoMed remains a small, loss-making biotechnology company, and its stock is trading below both its 50-day and 200-day moving averages. Without new clinical, regulatory, financing, or commercialization news, analyst estimate changes alone may not be enough to overcome concerns about cash needs and execution risk.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.